Par Drugs & Chemicals Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is -33.16% vs 2.37% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -82.29% vs 16.22% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -76.24% vs -0.16% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 300.00% vs -80.00% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

Compare Quarterly Results Of Par Drugs & Che. With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

19.61

19.89

-0.28

-1.41%

Other Operating Income

0.00

Total Operating income

19.61

19.89

-0.28

-1.41%

Raw Material Cost

8.85

14.59

-5.74

-39.34%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.06

-0.01

0.07

700.00%

Employee Cost

1.94

1.59

0.35

22.01%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

7.32

2.77

4.55

164.26%

Total Expenditure (Excl Depreciation)

18.17

18.94

-0.77

-4.07%

Operating Profit (PBDIT) excl Other Income

1.44

0.95

0.49

51.58%

Other Income

0.36

0.62

-0.26

-41.94%

Operating Profit (PBDIT)

1.80

1.57

0.23

14.65%

Interest

0.04

0.18

-0.14

-77.78%

Exceptional Items

0.00

Gross Profit (PBDT)

1.76

1.39

0.37

26.62%

Depreciation

0.93

0.25

0.68

272.00%

Profit Before Tax

0.83

1.14

-0.31

-27.19%

Tax

-0.02

0.36

-0.38

-105.56%

Provisions and contingencies

0.00

Profit After Tax

0.85

0.78

0.07

8.97%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

0.85

0.78

0.07

8.97%

Equity Capital

12.30

10.24

2.06

20.12%

Face Value

10.00

2.00

0.00

Reserves

99.68

0.00

99.68

Earnings per share (EPS)

0.69

0.15

0.54

360.00%

Diluted Earnings per share

0.69

0.15

0.54

360.00%

Operating Profit Margin (Excl OI)

7.34%

4.78%

0.00

2.56%

Gross Profit Margin

8.98%

6.99%

0.00

1.99%

PAT Margin

4.33%

3.92%

0.00

0.41%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 19.61 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -33.16% vs 2.37% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -12.18% vs -2.15% in Mar 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 0.85 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -82.29% vs 16.22% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -48.48% vs -55.65% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 1.44 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is -76.24% vs -0.16% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -40.74% vs -60.10% in Mar 2025

Quarterly - Interest

Interest 0.04 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 300.00% vs -80.00% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 100.00% vs -60.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 7.34%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025